drugset

drugset / Trial / NCT06289998

Study of Tamibarotene in Patients With ADPKD

NCT06289998 ↗

Phase 2 Active not recruiting 70 enrolled Rege Nephro Co., Ltd.

RandomizedParallel-groupTriple-blindTreatment

Summary

Clinical trial of tamibarotene in patients with Autosomal Dominant Polycystic Kidney Disease

Timeline

Start: 2023-12-22
Primary completion: 2025-12
Completion: 2025-12

Publications

St Pierre K, Cashmore BA, Bolignano D, Zoccali C, Ruospo M, Craig JC, Strippoli GF, Mallett AJ, Green SC, Tunnicliffe DJ. Interventions for preventing the progression of autosomal dominant polycystic kidney disease. Cochrane Database Syst Rev. 2024 Oct 2;10(10):CD010294. doi: 10.1002/14651858.CD010294.pub3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Tamibarotene	Small molecule	4 mg	—

Indications